AlphaStocks
5.7
Consider Buy

Novartis AG (NVS)

As of Sep 20, 2026, Novartis AG (NVS) scores 5.7/10 on AlphaStocks' five-model composite, #68 of 168 Health Care stocks. At $140, NVS trades 37% below its model fair value of $223.

Health Care

ADR

$140.37

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#68out of 168 in Health Care

Is NOVARTIS AG a Good Investment in 2026?

NOVARTIS AG (NVS) scores 5.7 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates NOVARTIS AG as Strong (9/9). The Graham model is the least favorable, rating it Neutral. NOVARTIS AG currently trades 37% below its estimated fair value of $223. NOVARTIS AG ranks #68 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E19.6ROE31.5Market Cap274BDiv Yield2.6

Estimated Fair Value

$223.1737% below

Trading below estimated fair value. EPS grew 22% year-over-year. ROE of 32% signals strong profitability. P/E of 20x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

9/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Strong

Growth rate vs price (PEG)

Greenblatt

Attractive

Earnings yield 6.1% · ROC >100%

Frequently Asked Questions

Is NOVARTIS AG (NVS) a good investment?
As of Sep 20, 2026, Novartis AG (NVS) scores 5.7/10 on AlphaStocks' five-model composite, #68 of 168 Health Care stocks. At $140, NVS trades 37% below its model fair value of $223. That is a middle-of-the-pack score with no strong signal either way.
What is NOVARTIS AG's Piotroski F-Score?
NOVARTIS AG's Piotroski F-Score status is Strong. The raw score is 9/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is NVS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $223, NVS appears undervalued. The stock currently trades 37% below its estimated fair value. Trading below estimated fair value. EPS grew 22% year-over-year. ROE of 32% signals strong profitability. P/E of 20x is moderate for this quality level.
How does NVS compare to other Health Care stocks?
NOVARTIS AG ranks #68 out of 168 stocks in the Health Care sector, placing it in the top 40% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about NVS?
AlphaStocks evaluates NVS using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Strong; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 5.7/10.

Similar Stocks

INSPABBVINCY

Compare NVS with

INSP vs NVSABBV vs NVSINCY vs NVS

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer